Methyltransferases in myelodysplastic syndromes: Guilty or not guilty?

Leukemia Research

Volumn 33, Issue 5, 2009, Pages 601-602

  Quesnel, Bruno ^a,b  

^a Institut de Recherche sur le Cancer de Lille   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

DNMT; Epigenetic; Hematopoiesis; Methylation; Methyltransferases; Myelodysplastic

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE;

CELL DIFFERENTIATION; CELL LINEAGE; EDITORIAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION;

CELL DIFFERENTIATION; DNA METHYLATION; HUMANS; METHYLTRANSFERASES; MYELODYSPLASTIC SYNDROMES;

EID: 61649092556     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.11.004     Document Type: Editorial

References (21)

1. Jiang Y., Dunbar A., Gondek L.P., Mohan S., Rataul M., O'Keefe C., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood October (2008)
2. Uchida T., Kinoshita T., Hotta T., and Murate T. High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. Leukemia & lymphoma 32 (1998) 9-18
3. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91 (1998) 2985-2990
4. Zilberman D., Coleman-Derr D., Ballinger T., and Henikoff S. Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 456 September (2008) 125-129
5. Venkatasubrahmanyam S., Hwang W.W., Meneghini M.D., Tong A.H., and Madhani H.D. Genome-wide, as opposed to local, antisilencing is mediated redundantly by the euchromatic factors Set1 and H2A.Z. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 16609-16614
6. Sarcinella E., Zuzarte P.C., Lau P.N., Draker R., and Cheung P. Monoubiquitylation of H2A.Z distinguishes its association with euchromatin or facultative heterochromatin. Molecular and Cellular Biology 27 (2007) 6457-6468
7. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., et al. High-resolution profiling of histone methylations in the human genome. Cell 129 (2007) 823-837
8. Meneghini M.D., Wu M., and Madhani H.D. Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin. Cell 112 (2003) 725-736
9. Langer F., Dingemann J., Kreipe H., and Lehmann U. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leukemia Research 29 (2005) 325-329
10. Quesnel B. Methylation and myelodysplastic syndromes: when and where?. Leukemia Research 30 (2006) 1327-1329
11. Hofmann W.K., Takeuchi S., Takeuchi N., Thiel E., Hoelzer D., and Koeffler H.P. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. Leukemia Research 30 (2006) 1347-1353
12. Sakashita K., Koike K., Kinoshita T., Shiohara M., Kamijo T., Taniguchi S., et al. Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. The Journal of Clinical Investigation 108 (2001) 1195-1204
13. Hopfer O., Komor M., Koehler I.S., Freitag C., Schulze M., Hoelzer D., et al. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leukemia Research Sep 29 (2008) [Epub ahead of print]PMID: 18829110
14. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295 (2002) 1079-1082
15. Gartel A.L. A new mode of transcriptional repression by c-myc: methylation. Oncogene 25 (2006) 1989-1990
16. Suzuki M., Yamada T., Kihara-Negishi F., Sakurai T., Hara E., Tenen D.G., et al. Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. Oncogene 25 (2006) 2477-2488
17. Zhang Q., Wang H.Y., Liu X., and Wasik M.A. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nature Medicine 13 (2007) 1341-1348
18. Cattaneo F., and Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. Journal of Cellular Biochemistry 105 (2008) 344-352
19. Spensberger D., and Delwel R. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Letters 582 (2008) 2761-2767
20. Kangaspeska S., Stride B., Metivier R., Polycarpou-Schwarz M., Ibberson D., Carmouche R.P., et al. Transient cyclical methylation of promoter DNA. Nature 452 (2008) 112-115
21. Metivier R., Gallais R., Tiffoche C., Le Peron C., Jurkowska R.Z., Carmouche R.P., et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 452 (2008) 45-50